Bio-Rad Laboratories anti-biotherapeutic and anti-MMAE antibodies
Bio-Rad Laboratories has launched four anti-idiotypic antibodies to the drugs atezolizumab (Lemtrada), avelumab (Bavencio), obinutuzumab (Gazyvaro) and ocrelizumab (Ocrevus), extending its range of anti-biotherapeutic antibodies. It has also introduced its anti-monomethyl auristatin E (MMAE) biotherapeutic antibody range for bioanalysis.
The company’s range of ready-made anti-biotherapeutic antibodies enables the development of robust bioanalytical assays against marketed biologic drugs. The anti-idiotypic antibodies are suitable for pharmacokinetic (PK) and antidrug-antibody assays for atezolizumab, avelumab, obinutuzumab and ocrelizumab, enabling therapeutic drug monitoring for innovator and biosimilar products.
The anti-MMAE antibody range supports bioanalysis of antibody-drug conjugates (ADCs) carrying MMAE as payload. MMAE is a potent antimitotic agent that inhibits cell division. Due to its toxicity, MMAE is not used as a drug itself, but instead forms the payload component of ADCs. The anti-MMAE biotherapeutic antibodies enable the development of sensitive assays for both ADCs incorporating the toxin and the toxin itself.
Phone: 02 9914 2800
EpigenTek EpiQuik CUT&RUN m6A RNA Enrichment (MeRIP) Kit
The kit is a complete set of optimised buffers and reagents designed to enrich an RNA fragment...
Cayman Chemical Off-Patent Drug Screening Library (96-Well)
Featuring a curated collection of FDA-approved compounds that are no longer covered under...
Norgen Biotek Bacterial EV Isolation Kit
The Bacterial EV Isolation Kit enables researchers to isolate extracellular vesicles directly...
